MBX

CARMEL, Ind. and BURLINGTON, Mass., April 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will host an in-person and virtual Obesity Day on Monday, May 11, 2026 at 10:30 a.m. ET to provide an update on its expanding obesity portfolio of products. For more details and to register for the event, click here. The event will feature Richard DiMarchi, Ph.D. (Distinguished Professor of Chemistry, Indiana University; Scientific Co-Founder, MBX Biosciences, Inc.) a

144 - MBX Biosciences, Inc. (0001776111) (Subject)

DEFA14A - MBX Biosciences, Inc. (0001776111) (Filer)

DEF 14A - MBX Biosciences, Inc. (0001776111) (Filer)

4/A - MBX Biosciences, Inc. (0001776111) (Issuer)

4/A - MBX Biosciences, Inc. (0001776111) (Issuer)

CARMEL, Ind., April 03, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the issuance of an equity inducement award to Karen Basbaum in connection with her commencement of employment as the company's new Chief Business Officer. The inducement award consisted of non-qualified stock options to purchase an aggregate of 130,000 shares of the company's common stock with an exercise price of $32.29 per share, which is equal to the closing price of the company's common stock

144 - MBX Biosciences, Inc. (0001776111) (Subject)

3 - MBX Biosciences, Inc. (0001776111) (Issuer)

144 - MBX Biosciences, Inc. (0001776111) (Subject)

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

S-3ASR - MBX Biosciences, Inc. (0001776111) (Filer)

S-8 - MBX Biosciences, Inc. (0001776111) (Filer)

10-K - MBX Biosciences, Inc. (0001776111) (Filer)

8-K - MBX Biosciences, Inc. (0001776111) (Filer)

Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026 Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029 CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stag

CARMEL, Ind., March 10, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Karen Basbaum, MBA, as Chief Business Officer (CBO). Ms. Basbaum brings more than two decades of leadership in corporate strategy, business development, and strategic transactions across the biotechnology and pharmaceutical industries. "Karen is a highly accomplished and strategic leader with a proven track record of sourcing, structuring, and executing high-value partnerships

In the fourth paragraph, we are replacing milligrams with micrograms. The corrected press release follows. CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) to discuss the overall Phase 3 trial design for once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP). "We are very encouraged by the outcome of our End-of-

8-K - MBX Biosciences, Inc. (0001776111) (Filer)

CARMEL, Ind., March 09, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) to discuss the overall Phase 3 trial design for once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP). "We are very encouraged by the outcome of our End-of-Phase 2 meeting and the constructive feedback supporting our planned Phase 3 trial for canvuparatide," said

4 - MBX Biosciences, Inc. (0001776111) (Issuer)

8-K - MBX Biosciences, Inc. (0001776111) (Filer)

CARMEL, Ind., Feb. 23, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will participate in the following upcoming March investor conferences: Citizens Life Sciences Conference Date: Tuesday, March 10, 2026Format: Fireside chat and 1x1 meetingsTime: 9:00 a.m. – 9:25 a.m. ETLocation: Miami, FL UBS Biotech Summit Miami – Catalyst for Change Date: Tuesday, March 10

SCHEDULE 13D/A - MBX Biosciences, Inc. (0001776111) (Subject)

CARMEL, Ind., Feb. 11, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that Kent Hawryluk, President and Chief Executive Officer, and Sam Azoulay, M.D., Chief Medical Officer, will present at and participate in the following upcoming investor conferences: 36th Oppenheimer Annual Healthcare Life Sciences Conference (Virtual) Date: Wednesday, February 25, 2026Format: Fireside chat and 1x1 meetingsTime: 11:20 a.m. – 11:50 a.m. ET TD Cowen 46th Annual Health Care Confe